Loading…
Cogent Biosciences, Inc. is projected to rise to $40.82 by 2027, a +18% move from its current price of $34.51. COGT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $33.78 | $34.51 | $35.25 | 0.00% |
| May 30 | $33.49 | $34.51 | $35.56 | -0.01% |
| May 31 | $33.26 | $34.51 | $35.80 | -0.01% |
| Jun 1 | $33.07 | $34.50 | $36.00 | -0.02% |
| Jun 2 | $32.90 | $34.50 | $36.18 | -0.02% |
| Jun 3 | $32.75 | $34.50 | $36.34 | -0.03% |
| Jun 4 | $32.61 | $34.50 | $36.49 | -0.03% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $32.61 | $34.50 | $36.49 | -0.03% |
| Week 2 | $31.85 | $34.49 | $37.34 | -0.06% |
| Week 3 | $31.28 | $34.48 | $38.00 | -0.09% |
| Week 4 | $30.80 | $34.47 | $38.57 | -0.12% |
| Week 5 | $30.39 | $34.46 | $39.07 | -0.15% |
| Week 6 | $30.02 | $34.45 | $39.53 | -0.19% |
| Week 7 | $29.68 | $34.44 | $39.95 | -0.22% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor.
Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib.
Cogent Biosciences, Inc. (COGT) operates in the Healthcare sector. The current price is $32.67 and the market cap is $5.58B, with a rank of 1268. The 30-day technical picture shows bullish sentiment with RSI14 at 40; the SMA50 is $35.40 and the SMA200 is $29.16.
The stock trades with support at $31.25 and resistance at $37.25, and the 30-day range spans $28.45 to $37.52. Forecast highlights show a multi-year upside, with the 2026 avg price at $32.67 and projected growth to 2050 avg price of $280.83, with substantial ROIs along the way.
A major floor 17.9% below — a decisive break under it would weaken the trend.
The nearest floor, 9.4% below — buyers have tended to step in here.
The nearest ceiling, 7.9% above — a clean break opens room to run.
A major ceiling 16.9% above — clearing it would confirm fresh momentum.
Key COGT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of COGT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $33.32 | Buy | $33.54 | Buy |
| MA 10 | $33.04 | Buy | $33.50 | Buy |
| MA 20 | $34.32 | Buy | $34.08 | Buy |
| MA 50 | $35.38 | Sell | $35.08 | Sell |
| MA 100 | $36.30 | Sell | $34.36 | Buy |
| MA 200 | $29.39 | Buy | $29.81 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.47 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 9.51 | Neutral |
| Williams %R (14) | -7.91 | Info |
| MACD (12,26,9) | 0.06 | Buy |
| ROC (12) | -0.66 | Sell |
| Bollinger %B (20,2) | 0.53 | Neutral |
| Stochastic %K (14) | 92.09 | Sell |
| TRIX (15) | -0.34 | Sell |
| Awesome (5,34) | -1.94 | Sell |
| Ultimate (7,14,28) | 56.89 | Neutral |
| Momentum (10) | -0.02 | Sell |
| Aroon Osc (25) | -40.00 | Sell |
| Hull MA (9) | 33.85 | Buy |
| ADX (14) | 17.02 | Neutral |
| ATR (14) | 0.64 | Info |
The 30-day technical picture is bullish. The RSI14 is 40, and the stock trades near a bullish setup with a 50-day simple moving average of $35.40 and a 200-day simple moving average of $29.16. Support sits at $31.25 and resistance at $37.25, with a 30-day range of $28.45 to $37.52.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $31.25 | $34.51 | $47.19 | 0% | Neutral | |
| $33.07 | $40.82 | $52.93 | +18% | Neutral | |
| $36.20 | $45.62 | $60.87 | +32% | Bullish | |
| $38.20 | $48.96 | $66.85 | +42% | Bullish | |
| $40.66 | $52.91 | $73.65 | +53% | Bullish | |
| $48.78 | $64.36 | $91.14 | +87% | Bullish | |
| $55.88 | $74.66 | $107.37 | +116% | Bullish | |
| $60.51 | $81.83 | $119.33 | +137% | Bullish | |
| $65.13 | $89.08 | $131.61 | +158% | Bullish | |
| $68.22 | $94.32 | $141.04 | +173% | Bullish | |
| $101.72 | $147.61 | $232.28 | +328% | Bullish | |
| $175.65 | $276.55 | $469.26 | +701% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $31.25 | $34.51 | $40.46 | +0.00% |
| June 2026 | $29.36 | $34.32 | $40.93 | -0.56% |
| July 2026 | $29.22 | $34.37 | $41.44 | +0.16% |
| August 2026 | $29.90 | $35.35 | $42.97 | +2.86% |
| September 2026 | $30.04 | $35.67 | $43.64 | +0.88% |
| October 2026 | $29.78 | $35.49 | $43.69 | -0.48% |
| November 2026 | $30.51 | $36.49 | $45.15 | +2.80% |
| December 2026 | $31.63 | $37.95 | $47.19 | +3.99% |
Click any year to see its month-by-month COGT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect COGT to range from $31.25 to $47.19 through 2026. The $34.51 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The COGT price prediction for 2027 points to an average of $40.82 (low $33.07, high $52.93) — a potential gain of +18% on today's $34.51. A consolidation phase looks the most probable path here.
In 2028, COGT is projected to trade between $36.20 and $60.87, averaging $45.62 — a potential gain of +32% from today's $34.51. That is up +12% on the projected 2027 average. Momentum favours further upside here.
Cogent Biosciences, Inc.'s 2029 outlook centres on $48.96, within a $38.20 to $66.85 range. That is up +7% on the projected 2028 average. That marks a +42% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, COGT could reach as high as $73.65, with a base case around $52.91 and support toward $40.66 — roughly +53% from $34.51. Momentum favours further upside here.
Expect COGT to range from $48.78 to $91.14 through 2031. The $64.36 average target implies a +87% move from current prices. That is up +22% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The COGT price prediction for 2032 points to an average of $74.66 (low $55.88, high $107.37) — a potential gain of +116% on today's $34.51. Momentum favours further upside here.
In 2033, COGT is projected to trade between $60.51 and $119.33, averaging $81.83 — a potential gain of +137% from today's $34.51. That is up +10% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Cogent Biosciences, Inc.'s 2034 outlook centres on $89.08, within a $65.13 to $131.61 range. That is up +9% on the projected 2033 average. That marks a +158% change versus current levels. Momentum favours further upside here.
By 2035, COGT could reach as high as $141.04, with a base case around $94.32 and support toward $68.22 — roughly +173% from $34.51. Buyers look set to stay in control over this stretch.
Expect COGT to range from $101.72 to $232.28 through 2040. The $147.61 average target implies a +328% move from current prices. That is up +57% on the projected 2035 average. Momentum favours further upside here.
The COGT price prediction for 2050 points to an average of $276.55 (low $175.65, high $469.26) — a potential gain of +701% on today's $34.51. Buyers look set to stay in control over this stretch.
Investing $1,000 in COGT today (≈ 28.977108 COGT) could be worth
$8,013.72
+$7,013.72 (+701%) by 2050 · US Dollar
Based on the average projected COGT price of $276.55 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in COGTwould be worth at today's price.
$1,000 invested in COGT on May 27, 2025 (≈ 204.918028 COGT) would be worth
$7,071.72
+$6,071.72 (+607.2%) today · 7.07× · US Dollar
Based on a COGT entry price of $4.88 vs. today's $34.51.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $32.92 | $1,048.14 | +4.8% |
| 1 month ago | $36.6 | $942.77 | -5.7% |
| 3 months ago | $39.46 | $874.56 | -12.5% |
| 6 months ago | $40.22 | $858.03 | -14.2% |
| 1 year ago | $4.88 | $7,071.72 | +607.2% |
| All time (5.0y) ago | $8.4 | $4,108.33 | +310.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our COGT forecast.
Our base-case forecast reaches $69.00 around 2032.
Implied market cap at $69.00: $11.79B
The year by year forecast shows steady upside. In 2026 the average price is $32.67, with a min of $31.25 and a max of $45.00 and ROI of 0%. In 2027 the average rises to $38.96 with ROI of 19.3% and a neutral sentiment.
By 2028 the average is $44.04 and ROI 34.8% with a bullish sentiment, and in 2029 the average is $47.48 with ROI 45.4%. The 2030 forecast shows an average of $51.50 with ROI 57.6%. In 2031 the average is $63.59 (ROI 94.6%), and in 2032 it is $73.55 (ROI 125.1%).
In 2033 the average is $80.48 (ROI 146.3%), and in 2034 it is $88.73 (ROI 171.6%). In 2035 the average is $93.57 (ROI 186.4%). The 2040 forecast shows an average of $148.86 with ROI 355.6%, and by 2050 the average is $280.83 with ROI 759.6% and bullish sentiment.
These are estimates and not guarantees.
Tap a question to reveal the answer.
Min $39.63, Avg $51.50, Max $71.57; ROI 57.6%; Sentiment BULLISH.
The forecast shows neutral in 2026 with Avg $32.67 and neutral in 2027 with Avg $38.96, then bullish momentum with higher averages and ROIs in 2028–2050; these are estimates, not guarantees.
Yes. The forecast shows a max of $105.55 in 2032 and $117.11 in 2033.
$28.45 to $37.52.
Current price $32.67; Market cap $5.58B.
Cogent Biosciences, Inc. Community Discussion
0Share your Cogent Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.